SetPoint Starts Trial on Bioelectronic Therapy for Crohn’s Disease

SetPoint Starts Trial on Bioelectronic Therapy for Crohn’s Disease
SetPoint Medical, a biotech company developing therapies for inflammatory bowel diseases (IBD), announced that it is now evaluating safety and efficacy for its novel treatment for Crohn's disease. The announcement was made by the gastroenterologists responsible for the trial at the annual “Advances in Inflammatory Bowel Diseases” clinical and research conference hosted by the Crohn’s & Colitis Foundation in Orlando, Florida. The Valencia, California-based company will conduct the trial with patients suffering from moderately-to-severely active Crohn’s despite treatment with a tumor necrosis factor (TNF) antagonist drug, and it will be held at five different research centers in Europe. The investigators will stimulate the patients' vagus nerve with an implanted device in order to activate the natural inflammatory reflex of the body, and induce the production of the systemic anti-inflammatory effect. “Despite recent advances in therapy for Crohn’s most patients do not achieve full disease control and many who are adequately controlled seek alternatives to standard drug treatments” explained the coordinating investigator for the study, Geert D'Haens, who is a Professor of Gastroenterology at The University of Amsterdam's Academic Medical Center (AMC). “SetPoint’s approach has shown encouraging results in patients with rheumatoid arthritisand we look forward to evaluating its potential in Crohn’s patients in this important new study.” The novel platform being tested by SetPoint as a treatment for Crohn's disease is an implantable miniature neuromodulation device that includes a wireless charger and iPad app. It is able to stimulate the body's vagus nerve and, as a result, create a potent, systemic, anti-inflammatory effect. SetPoin
Subscribe or to access all post and page content.